Richard Pazdur, director of the FDA’s Oncology Center of Excellence, attributes the current shortage of two cancer drugs to drug companies that haven’t invested in building out their production capacity.
In an interview with The Cancer Letter, a weekly cancer publication, Pazdur said that the current shortages of cisplatin and carboplatin, a pair of drugs used to treat a wide range of cancer patients, are the result of two problems: manufacturers not investing in enhancing production capacity, and drug companies being dependent on one supplier of raw ingredients. The cisplatin shortage followed an inspection that revealed quality issues at a manufacturing facility, which then led to the shutdown of production. This led to a surge in carboplatin demand, creating a secondary shortage.
Unlock this story instantly and join 170,400+ biopharma pros reading Endpoints daily — and it’s free.
In a surprising turn of events, Matt Riddle has bid adieu to WWE, bringing his whirlwind career both inside and outside the WWE ring to a merciful close. In
BEIJING – A prominent Uyghur scholar specializing in the study of her people’s folklore and traditions has been sentenced to life in prison, according to a
Lauren Boebert revealed she has ‘peacefully parted ways’ with her Aspen bar owner theater date after the pair were caught on camera fondling each other a
In the ever-exciting world of anime, where anticipation runs high, ‘Zom 100: Bucket List of the Dead’ fans recently encountered an unexpected twist. The
